Drugs Made In America Acquisition Corp.
For the period ended Dec 31, 2024. Filed Mar 31, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 31, 2025
DMAA$10.890.0%Stored close · as of Nov 6, 2026
Contents
Statement of Changes in Shareholders’ Deficit
| Ordinary Shares · Additional Paid-in · Accumulated · Total Shareholders’ | |||||
|---|---|---|---|---|---|
| Shares | Amount | Capital | Deficit | Deficit | |
| Balance — May 23, 2024 (inception) | — | $— | $— | $— | $— |
| Issuance of Founder Shares to Sponsor(1)(2) | 9,857,143 | 986 | 34,014 | — | 35,000 |
| Net loss | — | — | — | (279,845) | (279,845) |
| Balance — December 31, 2024 | 9,857,143 | $986 | $34,014 | $(279,845) | $(244,845) |
| (1) | Includes an aggregate of up to 1,285,714 ordinary shares subject to surrender and forfeiture if the over-allotment option is not exercised in full by the underwriters (Note 5). In February 2025 the over-allotment option was exercised by the underwriters and these shares are no longer subject to forfeiture (Note 9). |
| (2) | On November 6, 2024, the Sponsor surrendered and forfeited 12,503,968 ordinary shares to the Company for no consideration, following which the Sponsor holds 9,857,143 ordinary shares (the “Founder Shares”). All share and per share data has been retrospectively presented. |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.